Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.transpact.in | |
Market Cap | 5.68 Cr. | |
Enterprise Value(EV) | 5.96 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -5.71 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 64.78 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 15.50 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 9.49 | Calculated using Price: 147.00 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.04 Cr. | 386,730 Shares |
FaceValue | 10 | |
Company Profile | ||
Transpact Enterprises, Maharashtra based is a biotechnology startup. It provides comprehensive & cost-effective products and solutions to specially-abled people. The company is continuously working towards technological innovations and interventions to improve their products. Transpact Enterprises mainly designs, develops and distributes Vestibulator, a therapeutic device. The device has been invented by the Society for Innovation and Entrepreneurship, lIT Bombay. And, Transpact Enterprises holds a license to carry out the commercial activities of Vestibulator. It is a co-patented technology of the company and IRCC-IIT Bombay. The company outsources the manufacturing of the device along with the design details to a 3rd party. With the help of advanced software, the company also offers customized device solutions for patients. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
+4.37% |
3 Month |
|
-0.88% |
6 Month |
|
-0.88% |
1 Year |
|
-4.55% |
2 Year |
|
+3.52% |
5 Year |
|
|
10 Year |
|
6 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -27.59 | -77.28 | -804.02 | -97.83 | -7.53 | -31.12 | |
Return on Capital Employed (%) | -19.45 | -27.62 | -66.20 | -53.57 | -5.23 | -21.88 | |
Return on Assets (%) | -19.19 | -25.93 | -60.34 | -47.48 | -4.78 | -17.80 |
Particulars | 6 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Shh. Funds | 0 | 0 | 0 | 1 | 1 | 1 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | |||
Curr. Liab. | 0 | 0 | 0 | 0 | 1 | 0 | |
Minority Int. | |||||||
Equity & Liab. | 0 | 0 | 1 | 1 | 1 | 1 | |
Non Curr. Assets | 0 | 0 | 0 | 1 | 1 | 1 | |
Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | |
Misc. Exp. not W/O | |||||||
Total Assets | 0 | 0 | 1 | 1 | 1 | 1 |
Particulars | 6 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Net Sales | 0 | 0 | 0 | ||||
Other Income | 0 | 0 | 0 | ||||
Total Income | 0 | 0 | 0 | 0 | |||
Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | |
PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | |||||||
Depreciation | 0 | 0 | 0 | 0 | |||
Taxation | 0 | 0 | 0 | ||||
Exceptional Items | |||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | |
Adjusted EPS | -2 | -3 | -11 | -11 | -2 | -6 |
Particulars | 6 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | -1 | 0 | 0 | |
Cash Fr. Inv. | 0 | 0 | 0 | ||||
Cash Fr. Finan. | 0 | 0 | 0 | 1 | 0 | ||
Net Change | 0 | 0 | 0 | 0 | |||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 |
Fri, 13 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate Under Reg 74(5) of SEBI (DP) Regulations 2018 for the Quarter Ended 31st December 2022 |
Fri, 21 Oct 2022
Board Meeting Outcome for Outcome Of The Board Meeting Dated 21.10.2022 Consider and approve the un-audited financial Results for the half year ended 30.09.2022 |
Tue, 18 Oct 2022
PCS Certification Under Reg 40(9) Of SEBI (LODR) Regulations 2015 PCS certification under reg 40(9) of SEBI (LODR) regulations 2015 for the half year ended 30th September 2022 |
Fri, 27 Jan 2023 |
|
|
|
|
|